Q1 Earnings Forecast for ANIP Issued By HC Wainwright

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report) - Stock analysts at HC Wainwright issued their Q1 2025 earnings estimates for ANI Pharmaceuticals in a research report issued on Monday, March 3rd. HC Wainwright analyst O. Livnat forecasts that the specialty pharmaceutical company will post earnings per share of $1.13 for the quarter. HC Wainwright has a "Buy" rating and a $94.00 price objective on the stock. The consensus estimate for ANI Pharmaceuticals' current full-year earnings is $3.86 per share. HC Wainwright also issued estimates for ANI Pharmaceuticals' Q2 2025 earnings at $1.31 EPS, Q3 2025 earnings at $1.13 EPS, Q4 2025 earnings at $1.53 EPS, FY2025 earnings at $5.10 EPS and FY2026 earnings at $5.81 EPS.

A number of other equities research analysts have also recently commented on ANIP. Leerink Partnrs raised ANI Pharmaceuticals to a "strong-buy" rating in a research note on Wednesday, December 11th. StockNews.com lowered shares of ANI Pharmaceuticals from a "hold" rating to a "sell" rating in a research note on Monday, March 3rd. Guggenheim upped their target price on shares of ANI Pharmaceuticals from $84.00 to $86.00 and gave the stock a "buy" rating in a research note on Wednesday, March 5th. Finally, Leerink Partners assumed coverage on shares of ANI Pharmaceuticals in a report on Wednesday, December 11th. They issued an "outperform" rating and a $80.00 price objective for the company. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus price target of $79.00.

Remove Ads

ANI Pharmaceuticals Stock Down 3.0 %

Shares of ANIP stock traded down $1.81 during trading hours on Thursday, hitting $58.81. 254,433 shares of the company's stock traded hands, compared to its average volume of 226,323. The company has a quick ratio of 1.97, a current ratio of 2.74 and a debt-to-equity ratio of 1.52. The stock's fifty day simple moving average is $57.76 and its two-hundred day simple moving average is $58.09. ANI Pharmaceuticals has a 12-month low of $52.50 and a 12-month high of $70.81. The stock has a market cap of $1.24 billion, a price-to-earnings ratio of -106.93 and a beta of 0.63.

Insider Buying and Selling at ANI Pharmaceuticals

In other ANI Pharmaceuticals news, CFO Stephen P. Carey sold 7,500 shares of the company's stock in a transaction that occurred on Tuesday, December 17th. The shares were sold at an average price of $55.79, for a total transaction of $418,425.00. Following the completion of the sale, the chief financial officer now directly owns 154,468 shares of the company's stock, valued at approximately $8,617,769.72. This represents a 4.63 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Krista Davis sold 1,000 shares of ANI Pharmaceuticals stock in a transaction on Friday, February 21st. The stock was sold at an average price of $60.20, for a total transaction of $60,200.00. Following the transaction, the senior vice president now owns 68,624 shares in the company, valued at $4,131,164.80. This represents a 1.44 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 10,300 shares of company stock valued at $584,009. 12.70% of the stock is owned by company insiders.

Hedge Funds Weigh In On ANI Pharmaceuticals

A number of institutional investors have recently bought and sold shares of ANIP. JPMorgan Chase & Co. increased its position in ANI Pharmaceuticals by 159.3% in the third quarter. JPMorgan Chase & Co. now owns 554,835 shares of the specialty pharmaceutical company's stock worth $33,101,000 after buying an additional 340,854 shares in the last quarter. Global Alpha Capital Management Ltd. raised its stake in ANI Pharmaceuticals by 1.8% during the 3rd quarter. Global Alpha Capital Management Ltd. now owns 536,450 shares of the specialty pharmaceutical company's stock worth $32,005,000 after acquiring an additional 9,500 shares during the period. Thompson Siegel & Walmsley LLC raised its stake in ANI Pharmaceuticals by 17.6% during the 3rd quarter. Thompson Siegel & Walmsley LLC now owns 230,159 shares of the specialty pharmaceutical company's stock worth $13,731,000 after acquiring an additional 34,416 shares during the period. Thrivent Financial for Lutherans boosted its position in shares of ANI Pharmaceuticals by 2.3% in the third quarter. Thrivent Financial for Lutherans now owns 13,028 shares of the specialty pharmaceutical company's stock worth $777,000 after purchasing an additional 299 shares during the period. Finally, Mizuho Markets Americas LLC bought a new position in shares of ANI Pharmaceuticals in the third quarter worth approximately $11,670,000. 76.05% of the stock is owned by institutional investors.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.